No connection

Search Results

IMRN vs SILO

IMRN
Immuron Limited
BEARISH
Price
$0.79
Market Cap
$8.1M
Sector
Healthcare
AI Confidence
85%
SILO
Silo Pharma, Inc.
BEARISH
Price
$0.52
Market Cap
$8.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
IMRN
--
SILO
--
Forward P/E
IMRN
-79.3
SILO
-0.74
P/B Ratio
IMRN
0.7
SILO
1.09
P/S Ratio
IMRN
1.08
SILO
116.19
EV/EBITDA
IMRN
-52.59
SILO
-0.1

Profitability

Gross Margin
IMRN
63.69%
SILO
38.57%
Operating Margin
IMRN
-47.16%
SILO
-4363.27%
Profit Margin
IMRN
-62.14%
SILO
0.0%
ROE
IMRN
-39.68%
SILO
-74.56%
ROA
IMRN
-21.93%
SILO
-35.63%

Growth

Revenue Growth
IMRN
4.8%
SILO
0.0%
Earnings Growth
IMRN
--
SILO
--

Financial Health

Debt/Equity
IMRN
0.02
SILO
--
Current Ratio
IMRN
8.04
SILO
11.36
Quick Ratio
IMRN
6.75
SILO
10.55

Dividends

Dividend Yield
IMRN
--
SILO
--
Payout Ratio
IMRN
0.0%
SILO
0.0%

AI Verdict

IMRN BEARISH

The deterministic health profile is weak, headlined by a Piotroski F-Score of 3/9, indicating significant financial deterioration. While the company maintains a strong liquidity position with a Current Ratio of 8.04 and negligible debt (D/E 0.02), these are offset by severe operational losses and a profit margin of -62.14%. The stock is in a clear long-term downtrend, losing over 85% of its value over five years, and the lack of recent earnings data suggests a lack of transparency or momentum. Despite trading below book value (P/B 0.70), the fundamental decay outweighs the valuation discount.

Strengths
Very low leverage with a Debt/Equity ratio of 0.02
Strong short-term liquidity (Current Ratio 8.04)
Trading at a discount to book value (P/B 0.70)
Risks
Weak financial health as evidenced by a Piotroski F-Score of 3/9
Severe negative profitability (Profit Margin -62.14%)
Extreme negative price momentum (1Y Change -51.9%)
SILO BEARISH

SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.

Strengths
Strong short-term liquidity (Current Ratio: 11.36)
Price/Book ratio near 1.09 suggests the stock is trading close to its accounting value
Recent short-term price momentum (+60.9% in 1 month)
Risks
Extreme fundamental weakness (Piotroski F-Score 0/9)
Zero revenue growth (YoY and Q/Q)
Massive operating losses (-4363.27% operating margin)

Compare Another Pair

IMRN vs SILO: Head-to-Head Comparison

This page compares Immuron Limited (IMRN) and Silo Pharma, Inc. (SILO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile